JP2023179436A5 - - Google Patents

Download PDF

Info

Publication number
JP2023179436A5
JP2023179436A5 JP2023138247A JP2023138247A JP2023179436A5 JP 2023179436 A5 JP2023179436 A5 JP 2023179436A5 JP 2023138247 A JP2023138247 A JP 2023138247A JP 2023138247 A JP2023138247 A JP 2023138247A JP 2023179436 A5 JP2023179436 A5 JP 2023179436A5
Authority
JP
Japan
Prior art keywords
isolated protein
seq
amino acid
protein
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023138247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023179436A (ja
Filing date
Publication date
Priority claimed from JP2020516534A external-priority patent/JP2020534007A/ja
Application filed filed Critical
Publication of JP2023179436A publication Critical patent/JP2023179436A/ja
Publication of JP2023179436A5 publication Critical patent/JP2023179436A5/ja
Pending legal-status Critical Current

Links

JP2023138247A 2017-09-22 2023-08-28 変異型ウイルスタンパク質 Pending JP2023179436A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17306255 2017-09-22
EP17306255.5 2017-09-22
JP2020516534A JP2020534007A (ja) 2017-09-22 2018-09-24 変異型ウイルスタンパク質
PCT/EP2018/075824 WO2019057974A1 (en) 2017-09-22 2018-09-24 GLYCOPROTEIN MUTATED FROM VESICULAR STOMATITIS VIRUS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020516534A Division JP2020534007A (ja) 2017-09-22 2018-09-24 変異型ウイルスタンパク質

Publications (2)

Publication Number Publication Date
JP2023179436A JP2023179436A (ja) 2023-12-19
JP2023179436A5 true JP2023179436A5 (enExample) 2024-07-05

Family

ID=60153233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020516534A Pending JP2020534007A (ja) 2017-09-22 2018-09-24 変異型ウイルスタンパク質
JP2023138247A Pending JP2023179436A (ja) 2017-09-22 2023-08-28 変異型ウイルスタンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020516534A Pending JP2020534007A (ja) 2017-09-22 2018-09-24 変異型ウイルスタンパク質

Country Status (14)

Country Link
US (8) US12091434B2 (enExample)
EP (3) EP4446337A3 (enExample)
JP (2) JP2020534007A (enExample)
CA (1) CA3076094A1 (enExample)
DK (1) DK3684786T3 (enExample)
ES (1) ES2991089T3 (enExample)
FI (1) FI3684786T3 (enExample)
HR (1) HRP20241466T1 (enExample)
HU (1) HUE069207T2 (enExample)
LT (1) LT3684786T (enExample)
PL (1) PL3684786T3 (enExample)
PT (1) PT3684786T (enExample)
SI (1) SI3684786T1 (enExample)
WO (1) WO2019057974A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4446337A3 (en) * 2017-09-22 2025-01-08 Centre National de la Recherche Scientifique Mutated glycoprotein of vesicular stomatitis virus
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof
CA3140115A1 (en) 2019-05-23 2020-11-26 Massachusetts Institute Of Technology Ligand discovery and gene delivery via retroviral surface display
EP4013459B1 (en) * 2019-08-16 2025-07-23 Mayo Foundation for Medical Education and Research Chimeric vesiculoviruses and methods of use
JP2023509966A (ja) * 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法
EP4100420A1 (en) * 2020-02-06 2022-12-14 Boehringer Ingelheim Vetmedica GmbH Polypeptides useful for detecting anti-rhabdovirus antibodies
WO2022013872A1 (en) * 2020-07-14 2022-01-20 Ichilov Tech Ltd. Pseudotyped viruses configured to express car in t-cells
EP4284821A1 (en) 2021-01-27 2023-12-06 Umoja Biopharma, Inc. Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
CN112852757A (zh) * 2021-02-01 2021-05-28 南京大学 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法
US20240218390A1 (en) 2021-02-26 2024-07-04 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
BR112023021075A2 (pt) * 2021-04-16 2023-12-12 Massachusetts Inst Technology Método para liberar um ou mais ácidos nucleicos a uma célula-tronco hematopoiética, e, método para edição de gene em uma célula-tronco hematopoiética
KR20240112950A (ko) * 2021-12-06 2024-07-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 조작된 세포 진입에 의한 수용체-리간드 특이성의 발견을 위한 방법 및 조성물
IL313473A (en) 2021-12-15 2024-08-01 Interius Biotherapeutics Inc Pseudotyped viral particles, compositions comprising the same, and uses thereof
IL291148A (en) * 2022-03-06 2023-10-01 Noga Therapeutics Ltd Lentiviral vectors for in vivo targeting of hematopoietic cells
AU2023272490A1 (en) 2022-05-17 2024-12-12 Umoja Biopharma, Inc. Manufacturing viral particles
TW202409288A (zh) 2022-07-25 2024-03-01 美商英特瑞斯生物療法公司 突變多肽、包含該等突變多肽之組合物及其用途
WO2024050450A1 (en) 2022-08-31 2024-03-07 Gigamune, Inc. Engineered enveloped vectors and methods of use thereof
WO2024098038A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Polynucleotide construct and related viral vectors and methods
WO2024098028A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Lentiviral particles displaying fusion molecules and uses thereof
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
KR20250160369A (ko) 2023-01-27 2025-11-12 리제너론 파마슈티칼스 인코포레이티드 변형된 랩도바이러스 당단백질 및 이의 용도
WO2024196738A2 (en) * 2023-03-17 2024-09-26 Kelonia Therapeutics, Inc. In vivo daric
KR20250167052A (ko) * 2023-04-10 2025-11-28 선전 제노큐리 바이오테크 컴퍼니 리미티드 돌연변이형 vsvg 및 표적화 벡터
WO2024216227A1 (en) 2023-04-12 2024-10-17 Vyriad Cd3-redirected vectors, components thereof, and uses of the vectors and components thereof
WO2024238153A1 (en) 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
WO2025006882A1 (en) * 2023-06-30 2025-01-02 The Children's Hospital Of Philadelphia Click chemistry assisted cell surface engineering for restoring lentivirus entry
WO2025017052A1 (en) * 2023-07-18 2025-01-23 Vivebiotech S.L. Purification resin and methods for using the same
TW202521554A (zh) * 2023-08-11 2025-06-01 美商克隆尼亞治療股份有限公司 用於修飾細胞的組成物
WO2025036498A1 (zh) * 2023-08-16 2025-02-20 深圳市济因生物科技有限公司 一种病毒载体及其在感染b细胞中的应用
WO2025072257A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Compositions for treating cancer
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer
US20250101122A1 (en) 2023-09-25 2025-03-27 Kelonia Therapeutics, Inc. Antigen binding polypeptides
WO2025072615A1 (en) 2023-09-29 2025-04-03 Orbital Therapeutics, Inc. Improved methods of making rna by splinted ligation and compositions thereof
WO2025102013A1 (en) 2023-11-10 2025-05-15 Vyriad Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof
WO2025162379A1 (zh) * 2024-02-01 2025-08-07 深圳市济因生物科技有限公司 一种多肽及包含所述多肽基因的病毒载体
WO2025189142A1 (en) 2024-03-08 2025-09-12 Vyriad Membraned vesicles and purification methods thereof
WO2025212851A2 (en) 2024-04-03 2025-10-09 Orbital Therapeutics, Inc. mRNA COMPOSITIONS AND USES THEREOF IN VARICELLA ZOSTER VIRUS VACCINES
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025231185A1 (en) 2024-05-01 2025-11-06 Legend Biotech Ireland Limited Viral glycoprotein variants and uses thereof
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
WO2025259931A1 (en) 2024-06-14 2025-12-18 Orbital Therapeutics, Inc. Compositions and methods for rna circularization
WO2025260074A1 (en) 2024-06-14 2025-12-18 Vyriad Multiplexing functional polypeptides and recombinant rhabdoviral g glycoproteins on enveloped delivery vehicles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716858B9 (en) * 1999-09-17 2009-08-12 Wellstat Biologics Corporation Oncolytic virus
NZ534492A (en) * 2002-02-07 2009-10-30 Novozymes Delta Ltd Albumin-fused kunitz domain peptides
JP4411523B2 (ja) * 2004-03-04 2010-02-10 株式会社日健総本社 抗ウイルス剤
US8008268B2 (en) * 2006-07-25 2011-08-30 Merial Limited Vaccines against vesicular stomatitis
AU2008285224B2 (en) * 2007-08-03 2015-01-22 Centre National De La Recherche Scientifique (Cnrs) Lentiviral gene transfer vectors and their medicinal applications
EP2020444B1 (en) * 2007-08-03 2017-05-31 Institut Pasteur Defective non-integrative lentiviral transfer vectors for vaccines
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
BR112015013669A2 (pt) * 2012-12-12 2017-11-14 Childrens Hospital Of Eastern Ontario Res Institute Inc composições e métodos para o tratamento de cânceres cerebrais
EP4446337A3 (en) 2017-09-22 2025-01-08 Centre National de la Recherche Scientifique Mutated glycoprotein of vesicular stomatitis virus

Similar Documents

Publication Publication Date Title
JP2023179436A5 (enExample)
FI4211231T3 (fi) Peptidimodifioitu aav-kapsidi
CN115246874B (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
WO2012172277A4 (en) Simian adenovirus and hybrid adenoviral vectors
WO2022206222A1 (zh) 一种新型冠状病毒s-rbd三聚体蛋白疫苗、其制备方法和应用
JP2013520426A5 (enExample)
JPWO2019193119A5 (enExample)
WO2021198706A3 (en) Coronavirus vaccines
CN113121702B (zh) 用于胞内递送分子的多聚化递送系统
AR125406A1 (es) Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
AR124216A1 (es) Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
CN115443288A (zh) 一种免疫球蛋白降解酶IdeE的突变体
MX2023008825A (es) Efecto sinergico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal.
JP2020517260A5 (enExample)
JPWO2021116462A5 (enExample)
CA2692358A1 (en) Recombinant human interferon-like proteins
JP2002539781A5 (enExample)
JPWO2021007529A5 (enExample)
JP7542830B2 (ja) 分子の細胞内送達のための複合体
JP2011521648A5 (enExample)
RU2017104284A (ru) Выделенные полипептиды cd44 и их применение
WO2024220461A3 (en) Aav capsid proteins having mutations in the vp1 region
JP2013502217A5 (enExample)
CN119487050A (zh) 用于提高病毒转导的组合物和方法
JPWO2022187424A5 (enExample)